|
DNAs inoculated groups
|
Trial 1
|
|---|
|
Weeks post inoculation
|
|---|
|
CD3+/CD4+
|
CD3+/CD8+
|
|---|
|
Week 2
|
Week 5
|
Week 2
|
Week 5
|
|---|
|
Control
|
2.23 ± 0.60
|
1.55 ± 0.26
|
0.91 ± 0.30
|
1.79 ± 0.58
|
|
pDisplay
|
2.55 ± 0.36
|
1.76 ± 0.14
|
1.16 ± 0.46
|
2.00 ± 0.35
|
|
pDis/H5
|
4.53 ± 0.33 *
|
4.19 ± 0.52* b
|
3.16 ± 0.56* a b
|
2.97 ± 0.55* a b
|
|
pDis/H5 + pDis/IL-15
|
6.98 ± 0.73* a c
|
6.28 ± 0.60* a c
|
1.94 ± 0.46*
|
1.64 ± 0.44
|
|
pDis/H5 + pDis/IL-18
|
4.46 ± 0.34*
|
3.45 ± 0.26*
|
2.31 ± 0.84*
|
1.95 ± 0.52
|
- Each value represents the mean percentages of T cell sub-populations ± SD. The percentage of CD3+/CD4+ and CD3+/CD8+ T cells before inoculation are recorded as 2.92 ± 0.40 and 0.52 ± 0.24, respectively. Statistically significant differences (P < 0.05) are indicated by an asterisk (*), treated compared with untreated groups; a, pDis/H5 compared with pDis/H5 + pDis/IL-15; b, pDis/H5 compared with pDis/H5 + pDis/IL-18; c, pDis/H5 + pDis/IL-15 compared with pDis/H5 + pDis/IL-18.
